November 2, 2018 10:41 AM EDT

J&J dumps PhII-ready CD28 autoimmune asset, returns rights to French partner

Amber Tong

J&J’s 5-year acquaintanceship with OSE Immunotherapeutics has come to an end as the pharma giant decided it doesn’t want the CD28 antagonist FR104 after all …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

J&J dumps PhII-ready CD28 autoimmune asset, returns rights to French partner

Amber Tong

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Updated: Galapagos to split into two companies, slash headcount as it eyes turnaround

Aiolos team reunites with $411M for new biotech with obesity drugs from China

Astellas stops developing autologous cell therapy using tech from Xyphos buyout

MaaT Pharma touts ‘unprecedented’ Phase 3 efficacy of graft-versus-host disease treatment

Pfizer, GSK add risk of Guillain-Barré to RSV vaccine labels at FDA's request

J&J dumps PhII-ready CD28 au­toim­mune as­set, re­turns rights to French part­ner

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

J&J dumps PhII-ready CD28 autoimmune asset, returns rights to French partner